Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer

Kumamoto University, Kumamoto, Kumamoto, Japan
International Journal of Oncology (Impact Factor: 3.03). 12/2004; 25(5):1303-9. DOI: 10.3892/ijo.25.5.1303
Source: PubMed


In our previous investigations, mitogen-activated protein kinase kinase 2 (MEK2)/extracellular signal-regulated kinase 2 (ERK2) signaling pathway was found to be correlated with the cell dissociation induced by dissociation factor (DF) in pancreatic cancer cells. In this study, the expressions of epidermal growth factor receptor (EGFR), phosphorylated EGFR (p-EGFR), and its downstream kinases MEK1/2 and ERK1/2, were analyzed to clarify the regulatory mechanism of cell dissociation in pancreatic cancer cells. Two hamster (PC-1.0 and PC-1) and two human (AsPC-1 and Capan-2) pancreatic cancer cell lines were used. Immunocytochemical study was performed using anti-EGFR, p-EGFR, phosphorylated MEK1/2 (p-MEK1/2), and phosphorylated ERK1/2 (p-ERK1/2) antibodies. DF-treatment markedly induced the expressions of EGFR, p-EGFR, p-MEK1/2, p-ERK1/2, as well as the dissociation of cell colonies in PC-1 and Capan-2 cells. In contrast, AG1478 (an EGFR inhibitor) treatment significantly induced the cell aggregation in PC-1.0 and AsPC-1 cells which usually grew as single cells, but strongly suppressed the expressions of EGFR, p-EGFR, p-MEK1/2, and p-ERK1/2. These observations demonstrate that activation of EGFR is closely involved in cell dissociation in pancreatic cancer through activating MEK/ERK signaling pathway.

93 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epidermal Growth Factor Receptor (EGFR or HER1) is considered a tumor associated antigen. HER1 is overexpressed in many human epithelial tumors and involved in crucial cellular functions for tumor development. For this reason HER1 is considered a good target for cancer immunotherapy and some passive agents are being evaluated in clinical trials. However, HER1-based active immunotherapy has not been clinically explored. To develop an active immunotherapy approach based on HER1 for the treatment of HER1+ cancer patients, we cloned and expressed in mammalian cells the HER1 extracellular domain protein (HER1-ECD), which was specifically recognized by an anti- EGFR monoclonal antibody. HER1-ECD was purified by affinity chromatography and adjuvated in Very Small Size Proteoliposomes (VSSP) or Complete Freund adjuvant to immunize C57BL/6 mice. Immunization elicited specific humoral and cellular immune response. The polyclonal antibodies induced by immunization recognized the full length HER1 on the surface of a lung tumor cell line. These results suggest that HER1-ECD could be an appropriated antigen to induce specific immune response in patients with HER1+ tumors.
    Full-text · Article · Apr 2008 · Biotecnologia Aplicada
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review describes the recent advances in the molecular events involved in pancreatic cancer initiation, progression, and metastasis. Additionally, the importance of deregulated cellular signaling elements as potential targets for developing novel therapeutic strategies against incurable forms of pancreatic cancer is reported. The emphasis is on the critical functions gained by numerous growth factors and their receptors, such as epidermal growth factor receptor, hedgehog signaling, and proangiogenic agents such as vascular endothelial factor and interleukin-8 for the sustained growth, survival, and metastasis of pancreatic cancer cells. The molecular mechanisms associated with antitumoral properties and the clinical benefits of gemcitabine alone or in combination with other cytotoxic agents for the treatment of pancreatic cancer are discussed.
    No preview · Article · Dec 2005 · Pancreas
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To clarify the involvement of matrix metalloproteinase-7 (MMP-7) in cell dissociation and the subsequent invasion of pancreatic cancer cells. Western blotting, in vitro invasion assay, immunocytochemistry, and immunohistochemistry were performed in pancreatic cancer cell lines or pancreatic cancer tissue. The active form of the MMP-7 protein was expressed exclusively in the conditioned medium of dissociated (PC-1.0 and AsPC-1) pancreatic cancer cells, whereas proMMP-7 protein was only detected in the conditioned medium of non-dissociated (PC-1 and Capan-2) cells. Both intracellular and conditioned medium localised MMP-7 was greatly reduced by treatment with the epidermal growth factor receptor (EGFR) inhibitor AG1478 and the mitogen activated protein kinase kinase (MEK) inhibitor U0126 in pancreatic cancer cells. MMP-7 treatment significantly induced the disruption of tight junction (TJ) structures and subsequent cell dissociation, and activation of the EGFR mediated MEK- ERK (extracellular signal regulated protein kinase) signalling pathway in the non-dissociated pancreatic cancer cells. Moreover, the strong in vitro invasiveness of dissociated cells was inhibited by AG1478 and U0126 treatment, whereas the weak invasiveness of non-dissociated cells was apparently induced by MMP-7 treatment. In addition, MMP-7 expression was stronger at the invasive front than at the centre of human pancreatic tumours. MMP-7 is involved in cell dissociation and the subsequent invasion of pancreatic cancer cells. It induces the disruption of TJ structures and forms a positive feedback loop with activation of the EGFR mediated MEK-ERK signalling pathway.
    Full-text · Article · Jan 2006 · Journal of Clinical Pathology
Show more